Literature DB >> 2783312

Hepatic osteodystrophy. Static and dynamic bone histomorphometry and serum bone Gla-protein in 80 patients with chronic liver disease.

T H Diamond1, D Stiel, M Lunzer, D McDowall, R P Eckstein, S Posen.   

Abstract

To study the pathogenesis of osteoporosis in patients with chronic liver disease, we performed dynamic bone histomorphometry and measured serum bone Gla-protein in 80 patients with various types of chronic liver disease. These results were compared with results obtained in 40 healthy controls. Mean trabecular bone volume and mean trabecular thickness were significantly reduced in both men and women with chronic liver disease (p less than 0.001 for both measurements in men and p less than 0.01 for both measurements in women). Osteoporosis as defined by histologic parameters was present in 17 (21%) patients with no significant differences in prevalence rates among the various hepatic disorders. No patient had histologic evidence of osteomalacia, although mineralization lag times were prolonged (p less than 0.01 for men and women). Bone formation rates were significantly reduced in 46 (57%) patients, and unlike the static measurements, were related to the type and severity of the underlying liver disease. Patients with alcoholic liver disease, hemochromatosis, and cholestatic liver disease had lower bone turnover rates and osteoblastic surfaces (p less than 0.001 and p less than 0.05, respectively) than patients with chronic active hepatitis. Furthermore, the presence of hepatic cirrhosis was associated with diminished bone formation and lower osteoblast surfaces. Serum bone Gla-protein levels were significantly correlated with bone formation rates and osteoblast surfaces (r = 0.585 and r = 0.434, respectively). A reduction in osteoblast surfaces has not previously been demonstrated in liver disease. This reduction and the associated impairment of osteoblastic activity may contribute to the pathogenesis of osteoporosis and can be assessed by the measurement of serum bone Gla-protein.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2783312

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  49 in total

1.  Bone status in a mouse model of genetic hemochromatosis.

Authors:  P Guggenbuhl; P Fergelot; M Doyard; H Libouban; M-P Roth; Y Gallois; G Chalès; O Loréal; D Chappard
Journal:  Osteoporos Int       Date:  2010-10-26       Impact factor: 4.507

2.  Serum markers of bone formation in parenteral nutrition patients.

Authors:  E W Lipkin; S M Ott; G L Klein; L J Deftos
Journal:  Calcif Tissue Int       Date:  1990-08       Impact factor: 4.333

3.  Does iron affect osteoblast function? Studies in vitro and in patients with chronic liver disease.

Authors:  T Diamond; R Pojer; D Stiel; A Alfrey; S Posen
Journal:  Calcif Tissue Int       Date:  1991-06       Impact factor: 4.333

4.  Bone disorders in experimentally induced liver disease in growing rats.

Authors:  Viktória Ferencz; Csaba Horváth; Béla Kári; János Gaál; Szilvia Mészáros; Zsuzsanna Wolf; Dalma Hegedus; Andrea Horváth; Anikó Folhoffer; Ferenc Szalay
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

5.  Hepatic osteodystrophy and liver cirrhosis.

Authors:  Vedat Goral; Mehmet Simsek; Nuriye Mete
Journal:  World J Gastroenterol       Date:  2010-04-07       Impact factor: 5.742

6.  Bone mineral densities in individuals with Gilbert's syndrome: a cross-sectional, case-control pilot study.

Authors:  G Y Minuk; R Greenberg; J Uhanova; K Hawkins; W D Leslie
Journal:  Can J Gastroenterol       Date:  2009-06       Impact factor: 3.522

7.  Effect of liver dysfunction on circulating sclerostin.

Authors:  Yumie Rhee; Won Jin Kim; Ki Jun Han; Sung Kil Lim; Se Hwa Kim
Journal:  J Bone Miner Metab       Date:  2013-10-15       Impact factor: 2.626

8.  Significance of albumin in the pathogenesis of osteoporosis: bone changes in genetically analbuminemic rats and rats fed a low albumin diet.

Authors:  H Morii; A Shioi; M Inaba; H Goto; T Kawagishi; K Nakatsuka; Y Nishizawa; H Takahashi; H Sone; T Katsumata
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

Review 9.  Bone disease after liver transplantation.

Authors:  M S Losowsky; S H Hussaini
Journal:  Gut       Date:  1996-10       Impact factor: 23.059

10.  Reduced Serum IGF-1 Associated With Hepatic Osteodystrophy Is a Main Determinant of Low Cortical but Not Trabecular Bone Mass.

Authors:  Zhongbo Liu; Tianzhen Han; Haim Werner; Clifford J Rosen; Mitchell B Schaffler; Shoshana Yakar
Journal:  J Bone Miner Res       Date:  2017-11-06       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.